SHAREHOLDER ALERT: TUFN ANAB HAFC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

NEW YORK, NY / ACCESSWIRE / April 30, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Tufin Software Technologies Ltd. (NYSE: TUFN)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/tufin-software-technologies-ltd-loss-submission-form?prid=6266&wire=1
Lead Plaintiff Deadline: June 5, 2020
Class Period: securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Tufin's April 2019 initial public offering

Allegations against TUFN include that: (1) Tufin's customer relationships and growth metrics were overstated, particularly with respect to North America; (2) Tufin's business was deteriorating, primarily in North America; (3) as a result, Tufin's representations regarding its sustainable financial prospects were overly optimistic; and (4) as a result, the Offering Documents were materially false and/or misleading and failed to state information required to be stated therein.

AnaptysBio, Inc. (NASDAQ: ANAB)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/anaptysbio-inc-loss-submission-form?prid=6266&wire=1
Lead Plaintiff Deadline: May 26, 2020
Class Period: October 10, 2017 to November 7, 2019

Allegations against ANAB include that: (i) AnaptysBio failed to disseminate important data from the Company's Phase 2a trial in atopic dermatitis, including the timing and extent of patients' use of topical corticosteroids as a rescue therapy during the study and whether any of the patients that utilized rescue therapy were classified as responders at a given time;and (ii) the Company's statements omitted key information from the Company's Phase 2a trial in peanut allergy, including patients' average cumulative peanut dose tolerated at day 14 after the administration of etokimab or placebo as well as whether the Company's decision to exclude 20% of the patients enrolled in the study from the interim analysis due to their mild symptoms was retrospective; and (ii) as a result of the foregoing, Defendants' positive statements about the efficacy and prospects of AnaptysBio's lead drug asset in the treatment of atopic dermatitis and peanut allergy were materially false and/or misleading and/or lacked a reasonable basis.

Hanmi Financial Corporation (NASDAQ: HAFC)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/hanmi-financial-corporation-loss-submission-form?prid=6266&wire=1
Lead Plaintiff Deadline: May 26, 2020
Class Period: August 12, 2019 to January 28, 2020

Allegations against HAFC include that: (1) the $40.7 million troubled loan that the Company disclosed on conference calls would necessitate further and future specific provisions for the Company – in the millions; (2) the same $40.7 million troubled loan would necessitate the Company to appraise and take personal property securing a portion of the amount of the loan; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 587741